In a study published this month in the Journal of Clinical Oncology, the results of a clinical trial of the drug bevacizumab to treat colon cancer in combination with the standard therapy found that the drug did not significantly increase disease-free survival in patients with stage II and stage III colon cancer.
Cell signaling protein may hold key to blocking long-studied genetic mutation
$11.9 Million in awards to address cancer disparities
N.C. native John Isner and doubles partner Sam Querrey to host
ABC Anchor Robin Roberts Guest of Honor at Kickoff Event
Project Focuses on Efficient, Low-Cost Genetic Analysis